Washington, DC, United States
Washington, DC, United States

Time filter

Source Type

Patent
Perseus Inc. and Chugai Seiyaku Kabushiki Kaisha | Date: 2014-12-11

A method for diagnosing cancer comprising detecting ROBO1 protein is disclosed. In addition, a method for treating a disease caused by abnormal cell growth comprising administrating an antibody that binds to ROBO1, as well as a pharmaceutical composition, a cell growth inhibitor and an anticancer agent comprising an antibody that binds to ROBO1 as an active ingredient are disclosed. Further, a method for inducing cell damages in a ROBO1 expressing cell and a method for inhibiting the growth of a ROBO1 expressing cell by bringing a ROBO1 expressing cell into contact with an antibody that binds to ROBO1, are disclosed. Furthermore, a method for monitoring progression of hepatitis by detecting ROBO1 protein is disclosed.


Patent
University of Miyazaki and Perseus Inc. | Date: 2015-09-16

The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1,2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.


Patent
University of Miyazaki, Fujita Health University Hospital and Perseus Inc. | Date: 2016-07-13

It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.


Patent
Fujita Health University Hospital, Osaka University and Perseus Inc. | Date: 2016-06-29

It is an object of the present invention to provide a novel antibody having a high binding activity and a high neutralizing activity on influenza viruses. The present invention provides an antibody, which neutralizes H1 influenza virus and/or H5 influenza virus, wherein the antibody has a heavy chain variable region having CDRs consisting of a defined heavy chain first complementarity-determining region (VH CDR1), a defined heavy chain second complementarity-determining region (VH CDR2) and a defined heavy chain third complementarity-determining region (VH CDR3), and a light chain variable region having CDRs consisting of a defined light chain second complementarity-determining region (VL CDR2) and a defined light chain third complementarity-determining region (VL CDR3).


Patent
Perseus Inc. | Date: 2015-03-18

It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.


It is an object of the present invention to produce an anti-CDH3 humanized antibody having lower immunogenicity, and to provide an anti-CDH3 humanized antibody drug conjugate comprising the aforementioned anti-CDH3 humanized antibody that more efficiently kills cancer cells expressing CDH3. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody which comprises complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No. NITE BP-1536, and complementarity determining region sequences derived from the light chain variable region thereof, and which also comprises a heavy chain human subgroup III consensus framework sequence or a human germline sequence that is selected under optimal alignment as a framework region sequence of the heavy chain variable region, and a light chain human subgroup I consensus framework sequence or a human germline sequence that is selected under optimal alignment as a framework region sequence of the light chain variable region.


Patent
Perseus Inc. | Date: 2014-10-10

Object of the present invention is to provide various anti-podoplanin antibodies useful as a drug or reagent. The present invention provides an anti-podoplanin antibody or antigen-binding fragment thereof, each having an epitope in any of the following regions in the amino acid sequence of podoplanin represented by SEQ ID NO: 1: (i) from position 56 to position 80, (ii) from position 81 to position 103, (iii) from position 81 to position 88, and (iv) from position 25 to position 57.


Patent
Perseus Inc. | Date: 2015-08-19

There is provided a method of treating a patient comprising: screening a patient suffering from signs and/or symptoms of at least one medical condition secondary to increased sympathetic tone; selecting the patient for treatment by ablation of at least one neural structure containing sympathetic nerves to reduce the sympathetic tone, the neural structure comprises one or more of: celiac ganglion, superior mesenteric ganglion, inferior mesenteric ganglion, aorticorenal ganglion; selecting a target of at least one measureable parameter affected by the sympathetic tone; ablating at least a portion of the neural structure to deactivate the portion of the neural structure; monitoring changes in the at least one measureable parameter; comparing the at least one measureable parameter to the selected target; and performing another ablation of the same neural structure, and/or another neural structure, based on the comparison.


Patent
Perseus Inc. | Date: 2015-02-12

There is provided a method of treating a patient comprising: screening a patient suffering from signs and/or symptoms of at least one medical condition secondary to increased sympathetic tone; selecting the patient for treatment by ablation of at least one neural structure containing sympathetic nerves to reduce the sympathetic tone, the neural structure comprises one or more of: celiac ganglion, superior mesenteric ganglion, inferior mesenteric ganglion, aorticorenal ganglion; selecting a target of at least one measurable parameter affected by the sympathetic tone; ablating at least a portion of the neural structure to deactivate the portion of the neural structure; monitoring changes in the at least one measurable parameter; comparing the at least one measurable parameter to the selected target; and performing another ablation of the same neural structure, and/or another neural structure, based on the comparison.


It is an object of the present invention to produce an anti-CDH3 humanized antibody having lower immunogenicity, and to provide an anti-CDH3 humanized antibody drug conjugate comprising the aforementioned anti-CDH3 humanized antibody that more efficiently kills cancer cells expressing CDH3. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody which comprises complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No. NITE BP-1536, and complementarity determining region sequences derived from the light chain variable region thereof, and which also comprises a heavy chain human subgroup III consensus framework sequence or a human germline sequence that is selected under optimal alignment as a framework region sequence of the heavy chain variable region, and a light chain human subgroup I consensus framework sequence or a human germline sequence that is selected under optimal alignment as a framework region sequence of the light chain variable region.

Loading Perseus Inc. collaborators
Loading Perseus Inc. collaborators